Goldman Sachs Adjusts Price Target on Viatris to $14 From $13, Maintains Neutral Rating

NodeGuardian · 2026-03-15T13:33:22+00:00

Goldman Sachs raised Viatris' price target to $14 from $13, maintaining a Neutral rating. This change indicates a slight update in the bank's outlook for the pharmaceutical company.

NodeGuardian

2026-03-15 13:33:22

Abstract generation in progress

Goldman Sachs has increased its price target for Viatris (VTRS) to $14, up from $13, while reiterating a Neutral rating on the pharmaceutical company’s stock. This adjustment reflects a modest revision in the bank’s outlook for Viatris. The company’s stock is listed on the Nasdaq under the symbol VTRS.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.